Üremide Metabolizma Değişiklikleri
Üremi, böbrek fonksiyonlarında ilerleyici bozulma sonucundasıvı-elektrolit, hormon dengesizlikleri ve metabolikanormallikler gelişen klinik bir sendromdur. Böbreklerde yaşamsalbazı metabolik düzenleyicilerin (eritropoetin, aktif Dvitamini vb) sentezinin bozulması da bu değişikliklere önemlikatı› sağlar. Diyaliz öncesi ve diyaliz tedavisi sırasındatüm bu faktörler atheroskleroz gelişlimi, kardiyovasküler hastalık, malnütrisyon, anemi, renal osteodistrofi, hiperparatiroidizmvb. çok ciddi komplikasyonlar›n yanı sıra, hastalarınyaşam kalitesini ve prognozu önemli derecede etkileyen ciddisorunlara yol açar. Böbrek hastalıkları erken dönemde tanımlanır ve komplikasyonlar erken dönemde tedavi edilirse,hastalığın seyri iyileştirilebilir ve maliyeti azaltılabilir.
___
- 1. Alper AB, Shenava RG. Uremia. March 17 2010.
http://www.medscape.com (Eriflim Tarihi: 31.08.2010).
- 2. Carrero JJ, Witasp A, Stenvinkel P, et al. Visfatin is increased in
chronic kidney disease patients with poor appetite and correlates
negatively with fasting serum amino acids and triglyceride levels.
Nephrol Dial Transplant. Mar 2010;25(3):901-6.
Üremide Metabolizma De¤ifliklikleri
- 3. Levey AS, Atkins R, Coresh J , Cohen EP , Collins AJ, Eckardt KU,
Nahas ME, Jaber BL, Jadoul M,Levin A, Powe1 NR, Rossert J,
Wheeler DC, Lameire N and Eknoyan G. Chronic kidney disease as
a global public health problem: Approaches and initiatives – a
position statement from Kidney Disease Improving Global
Outcomes. Kidney International advance online publication, 13
June 2007; 1-13.
- 4. Cibulka R, Racek J, Vesela E. The importance of L-carnitine in
patients with chronic renal failure treated with hemodialysis (in
Czech). Vnitr Lek 2007;.51: 1108-1113.
- 5. Cibulka R, Racek J. Metabolic Disorders in Patients with Chronic
Kidney Failure Physiol. Res. 2007;56: 697-705.
- 6. Silver J: Molecular mechanisms of secondary hyperparathyroidism.
Nephrol Dial Transplant 2000;15: 2-7.
- 7. Porth CM. Pathophysiology Concepts of Altered Health States. 6th
ed. Philadelphia, Pa: Lippincott; 2002.
- 8. Price S, Wilson L. Pathophysiology: Clinical Concepts of Disease
Processes. 6th ed. St Louis, Mo: Mosby; 2003.
- 9. Metheny N. Fluid and Electrolyte Balance. 4th ed. Philadelphia, Pa:
Lippincott Williams & Wilkins; 2000.
- 10. Wallace M. Anatomy and physiology of the kidney. AORN J. 1998;
68:799-780, 803-804, 806, 808, 810-811, 813-816, 819-824,
827-828.
- 11. Ik›zler TA, W›ndgard RL, Harvell J, Shyr Y, Hak›m RM: Association
of morbidity with markers of nutrition and inflammation in chronic
hemodialysis patients: a prospective study. Kidney Int 1999; 55:
1945-1951.
- 12. National Kidney Foundation. K/DOQI clinical practice guidelines
for chronic kidney disease: guideline, assessment of proteinuria.
Available at: http://www.kidney.org /professionals/kdoqi/guide
lines_ckd /p5_lab_g5.htm. (Eriflim Tarihi 15.05. 2006).
- 13. Alvestrand A. Carbohydrate and insulin metabolism in renal failure.
Kidney Int Suppl 62: S48-S52, 1997.
- 14. Rigalleau V, Gin H: Carbohydrate metabolism in uremia. Curr Opin
Clin Nutr Metab Care 2005; 8: 463-869.
- 15. Shinohara K, Shoj› T, Emoto M, Tahara H, Koyama H, Ish›mura E,
M›k› T, Tabata T, N›sh›zawa Y: Insulin resistance as an independent
predictor of cardiovascular mortality in patients with end-stage renal
disease. J Am Soc Nephrol 2002; 13: 1894-1900.
- 16. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M,
Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U:
Insulin resistance, hyperlipidemia and hypertension in mice lacking
endothelial nitric oxide synthase. Circulation 2001; 104: 342-345.
- 17. Dirican M, Akça R, Sarandol E, Dilek K: Serum paraoxonase activity
in uremic predialysis and hemodialysis patients. J Nephrol 2004; 17:
813-818.
- 18. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of
End-Stage Renal Disease in the United States, National Institutes of
Health, National Institute of Health, National Institute of Diabetes
and Digestive and Kidney Diseases, Bethesda, Md. Available at:
http:// www.usrds.org/atlas.htm. (Eriflim Tarihi 15.05.2006).
- 19. Broscious SK, Castagnola J. Chronic Kidney Disease Acute
Manifestations and Role of Critical Care Nurses Cr›t›cal Care Nurse
August 2006; Vol 26, No. 4.
- 20. Heuther SE, McCance KL. Understanding Pathophysiology. 3rd ed.
St Louis, Mo: Mosby; 2004.
- 21. Snyder S, Pendergraph B: Detection and evaluation of chronic
kidney disease. Am Fam Physician 2005; 72: 1723-1732.
- 22. Nat›onal K›dney Foundat›on: K/DOQI, clinical practice guidelines
for managing dyslipidemias in chronic kidney disease, part 3,
guideline 4. 2006.
http://www.kidney.org/professionals/kdoqi/guidelines_lipids/iii.htm.
- 23. Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
Available at: http:// www.usrds.org/atlas.htm.
(Eriflim Tarihi: 15.05.2006).